Patient
SITE013-0056
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2025-10-29
Adverse events
6
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 258); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 231); relationship: not assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 217); relationship: NOT RELATED; serious criteria: hospitalization
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 156); relationship: not assessed
Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 55); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-21 (study day 40); relationship: NOT RELATED; serious criteria: hospitalization
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.